Long-term (52-week) results of a phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis (PALACE 1)

dc.contributor.author	Gómez-Reino Carnota, Juan Jesús
dc.date.accessioned	2017-06-07T07:13:02Z
dc.date.available	2017-06-07T07:13:02Z
dc.date.issued	2013
dc.identifier.issn	0340-1855
dc.identifier.uri	http://hdl.handle.net/20.500.11940/3940
dc.language.iso	eng
dc.title	Long-term (52-week) results of a phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis (PALACE 1)
dc.type	Publicación de congreso
dc.authorsophos	Kavanaugh, A
dc.authorsophos	Mease, P
dc.authorsophos	Adebajo, A
dc.authorsophos	Wollenhaupt, J
dc.authorsophos	Hu, A
dc.authorsophos	Shah, K
dc.authorsophos	Stevens, R
dc.authorsophos	Gomez-Reino, J
dc.identifier.isi	331709100256
dc.identifier.sophos	13844
dc.issue.number	Supl 2
dc.journal.title	ZEITSCHRIFT FUR RHEUMATOLOGIE
dc.organization	Servizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago - Complexo Hospitalario Universitario de Santiago::Reumatoloxía
dc.page.initial	131
dc.page.final	131
dc.rights.accessRights	openAccess
dc.typesophos	Comunicaciones a congresos
dc.volume.number	72

Ficheros en el ítem

Ficheros	Tamaño	Formato	Ver
No hay ficheros asociados a este ítem.